Non-Small Cell Lung Cancer (NSCLC) Market - Growth, Trends, Covid-19 Impact, And Forecasts (2022 - 2027)

Market Overview

The Non-small Cell Lung Cancer (NSCLC) market is projected to register a CAGR of 9.5% during the forecast period (2022-2027).

Covid-19 significantly affected the non-small cell lung cancer-related clinical trials across the world. Several market players halted their clinical trials due to a financial crisis in the year. For instance, according to ClinicalTrails.gov, it was observed that more than 200 interventional studies were halted during the period of March to April 2020 due to the emergence of COVID-19. Additionally, fluctuation in the market is mainly due to the disruption in the supply chain of raw materials and end products.

The growing number of patients suffering from non-small cell lung cancer across the world is one of the key drivers of the growth of the market. This is majorly due to the increasing number of people with unhealthy habits such as smoking, tobacco & alcohol consumption, high dose of supplements, and sedentary lifestyle across the world. Additionally, increasing pollution level in the air is also one of the major factors contributing to the increase in the number of patients. As per the statistics provided by the World Health Organization (WHO), 2.2 million patients were diagnosed with lung cancer in 2020, and non-small cell lung cancer accounted for nearly 85% of the share of all lung cancer patients. Thus, the availability of a large patient base and a further increasing number of non-small cell lung cancer patients resulted in the high demand for therapy to treat the patients.

• Recent approvals of new drugs are expected to accelerate the market growth during the forecast period. In February 2022, the Medicines and Healthcare products Regulatory Agency (MHRA) approved Genentech’s Tecentriq to treat early-stage non-small cell lung cancer. Similarly, in October 2021, the United States Food and Drug Administration (U.S. FDA) approved atezolizumab (Tecentriq, Genentech, Inc.) in the U.S. for stage II and IIIA non-small cell lung cancer patients. In March 2021, the FDA approved Pfizer’s Lorbrena (lorlatinib) to treat ALK-positive NSCLC patients in the U.S. Additionally, in October 2021, Ventana Medical Systems, Inc. received the U.S. FDA approval for VENTANA PD-L1 (SP263) Assay as a companion diagnostic device to select patients for Tecentriq. Hence, recent new drug approvals and the launch of companion diagnostics to select targeted patients are responsible for the growth of the market during the forecast period.

Scope of the Report

As per the scope of this report, non-small cell lung cancer is a type of epithelial lung cancer, excluding small-cell lung carcinoma. The non-small cell lung cancer market is segmented by Cancer Type (Squamous Cell Carcinoma, Adenocarcinoma, Large-cell Carcinoma), By Treatment (Chemotherapy, Targeted Therapy, Immunotherapy, Others), and Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America).

Report scope can be customized per your requirements. Click here.

Key Market Trends

The Targeted Therapy Segment is Expected to Hold a Major Market Share in the Non-Small Cell Lung Cancer Market

Targeted therapy drugs are often used to treat advanced lung cancers and are either used along with chemotherapy or used individually. Some of the major targeted therapy drugs to treat non-small cell lung cancer are Erlotinib (Tarceva), Gefitinib (Iressa), Afatinib (Gilotrif), Mobocertinib (Exkivity), Osimertinib (Tagrisso), and Dacomitinib (Vizimpro). These drugs targets mutated genes in the body and thereby avoid adverse effect on healthy cells. Investment by market players for the development of targeted therapy due to its advantages over standard chemotherapy and entry of these drugs in multiple countries across the world are likely to drive the market growth.

• Major genes affected during non-small cell lung cancer are the KRAS gene, EGFR gene, T790M, ALK gene, ROS1, BRAF gene, RET, and MET gene. Hence, targeted therapy targets these genes, avoid their proliferation, and thereby helps to treat non-small cell lung cancer. Investment by industry players for R&D activities responsible for the development of new treatments to treat various mutations during non-small cell lung cancer. For instance, in May 2021, the U.S.FDA approved Rybrevant (amivantamab-vmjw) first-line treatment for a specific type of genetic mutated non-small cell lung cancer in adult patients. Rybrevant is the first targeted therapy for patients with epidermal growth factor receptor (EGFR) exon 20 insertion mutations in the United States. The same day FDA approved Guardant Health Inc.’s Guardant360 CDx, a companion diagnostic for Rybrevant. Hence, approval and launch of such targeted therapy and their companion diagnostics are expected to propel the market growth during the forecast period. A strong pipeline of targeted therapy for non-small cell lung cancer is also expected to boost the market during the forecast period.

To understand key trends, Download Sample Report